Trial Profile

A clinical trial assessing TNX4200

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 02 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TNX 4200 (Primary)
Indications Viral infections
Focus Adverse reactions; First in man

Most Recent Events

02 Jul 2024 New trial record
01 Jul 2024 According to Tonix Pharmaceuticals media release, the company awarded up to $34 Million U.S. Department of Defense Contract for accelerated development of Broad-Spectrum Antiviral Program to support an Investigational New Drug (IND) submission and to fund a first-in-human Phase 1 clinical study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com